Hormonal
Exposure to endocrine-disrupting chemicals (EDCs) during critical developmental windows (fetal, neonatal, pubertal) causes long-term reproductive, metabolic, and oncological disorders in adulthood through non-traditional dose-response mechanisms and epigenetic modifications.
Minimize exposure to endocrine disruptors, especially during pregnancy and childhood. Reduce use of plastics containing BPA/phthalates, choose fresh foods over canned/processed when possible, and be aware of environmental contaminants. The risk is cumulative and developmental, so early life protection is critical.
Results from animal models, human clinical observations, and epidemiological studies converge to implicate EDCs as a significant concern to public health... The mechanisms of EDCs involve divergent pathways including (but not limited to) estrogenic, antiandrogenic, thyroid, peroxisome proliferator-activated receptor (PPAR), retinoid, and actions through other nuclear receptors... EDCs may affect not only the exposed individual but also the children and subsequent generations... effects may be transmitted not due to mutation of the DNA sequence, but rather through modifications to factors that regulate gene expression such as DNA methylation and histone acetylation.
Why this rating
The paper is a Scientific Statement synthesizing animal models, human clinical observations, and epidemiological studies, though direct causal links in humans are often described as indirect or partial.
Source
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
Evanthia Diamanti‐Kandarakis et al. · Endocrine Reviews · 2009
DOI 10.1210/er.2009-0002
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →